<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">35006266</PMID><DateCompleted><Year>2022</Year><Month>03</Month><Day>08</Day></DateCompleted><DateRevised><Year>2023</Year><Month>01</Month><Day>11</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">2168-6157</ISSN><JournalIssue CitedMedium="Internet"><Volume>79</Volume><Issue>2</Issue><PubDate><Year>2022</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>JAMA neurology</Title><ISOAbbreviation>JAMA Neurol</ISOAbbreviation></Journal><ArticleTitle>Safety and Effectiveness of Long-term Intravenous Administration of Edaravone for Treatment of Patients With Amyotrophic Lateral Sclerosis.</ArticleTitle><Pagination><StartPage>121</StartPage><EndPage>130</EndPage><MedlinePgn>121-130</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1001/jamaneurol.2021.4893</ELocationID><Abstract><AbstractText Label="IMPORTANCE">Intravenous edaravone is approved as a disease-modifying drug for patients with amyotrophic lateral sclerosis (ALS), but evidence for efficacy is limited to short-term beneficial effects shown in the MCI186-ALS19 study in a subpopulation in which efficacy was expected.</AbstractText><AbstractText Label="OBJECTIVE">To evaluate the long-term safety and effectiveness of intravenous edaravone therapy for patients with ALS in a real-world clinical setting.</AbstractText><AbstractText Label="DESIGN, SETTING, AND PARTICIPANTS">Multicenter, propensity score-matched cohort study conducted between June 2017 and March 2020 at 12 academic ALS referral centers associated with the German Motor Neuron Disease Network. Of 1440 patients screened, 738 were included in propensity score matching. Final analyses included 324 patients with ALS comprising 194 patients who started intravenous edaravone treatment (141 received &#x2265;4 consecutive treatment cycles; 130 matched) and 130 propensity score-matched patients with ALS receiving standard therapy. All patients had probable or definite ALS according to the El Escorial criteria, with disease onset between December 2012 and April 2019. Subgroups were defined by applying the MCI186-ALS19 study inclusion criteria to evaluate whether patients would have been considered eligible (EFAS) or ineligible (non-EFAS).</AbstractText><AbstractText Label="EXPOSURES">Intravenous edaravone plus riluzole vs riluzole only.</AbstractText><AbstractText Label="MAIN OUTCOMES AND MEASURES">Patient characteristics and systematic safety assessment for patients who received at least 1 dose of intravenous edaravone. Effectiveness assessment of edaravone was conducted among patients who received at least 4 treatment cycles compared with propensity score-matched patients with ALS who received only standard therapy. Primary outcome was disease progression measured by decrease in the ALS Functional Rating Scale-Revised (ALSFRS-R) score. Secondary outcomes were survival probability, time to ventilation, and change in disease progression before vs during treatment. To account for the matched design, patients receiving edaravone and their corresponding matched controls were regarded as related samples in disease progression analyses; stratification for propensity score quintiles was used for survival probability and time to ventilation analyses.</AbstractText><AbstractText Label="RESULTS">A total of 194 patients started intravenous edaravone treatment; 125 (64%) were male, and the median age was 57.5 years (IQR, 50.7-63.8 years). Potential adverse effects were observed in 30 cases (16%), most notably infections at infusion sites and allergic reactions. Disease progression among 116 patients treated for a median of 13.9 months (IQR, 8.9-13.9 months) with edaravone did not differ from 116 patients treated for a median of 11.2 months (IQR, 6.4-20.0 months) with standard therapy (ALSFRS-R points/month, -0.91 [95% CI, -0.69 to -1.07] vs -0.85 [95% CI, -0.66 to -0.99]; P&#x2009;=&#x2009;.37). No significant differences were observed in the secondary end points of survival probability, time to ventilation, and change in disease progression. Similarly, outcomes between patients treated with edaravone and matched patients did not differ within the EFAS and non-EFAS subgroups.</AbstractText><AbstractText Label="CONCLUSIONS AND RELEVANCE">This cohort study using propensity score matching found that, although long-term intravenous edaravone therapy for patients with ALS was feasible and mainly well tolerated, it was not associated with any disease-modifying benefit. Intravenous edaravone may not provide a clinically relevant additional benefit compared with standard therapy alone.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Witzel</LastName><ForeName>Simon</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maier</LastName><ForeName>Andr&#xe9;</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Centre for ALS and other Motor Neuron Diseases, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steinbach</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Thuringian Neuromuscular Center, Department of Neurology, University Hospital Jena, Jena, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Grosskreutz</LastName><ForeName>Julian</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Precision Neurology, University of L&#xfc;beck, L&#xfc;beck, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Jan C</ForeName><Initials>JC</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medical Center G&#xf6;ttingen, G&#xf6;ttingen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sarikidi</LastName><ForeName>Anastasia</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Petri</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Hannover Medical School, Hannover, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Ren&#xe9;</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technische Universit&#xe4;t Dresden, Dresden, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, Site Dresden, Dresden, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wolf</LastName><ForeName>Joachim</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Diakonissenkrankenhaus, Mannheim, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hermann</LastName><ForeName>Andreas</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Translational Neurodegeneration Section "Albrecht Kossel," Department of Neurology, University of Rostock, Rostock, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, Site Rostock/Greifswald, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Prudlo</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>DZNE, Site Rostock/Greifswald, Rostock, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Neurology, University Rostock, Rostock, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cordts</LastName><ForeName>Isabell</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technical University Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lingor</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Neurology, Technical University Munich, Munich, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>DZNE, Site Munich, Munich, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>L&#xf6;scher</LastName><ForeName>Wolfgang N</ForeName><Initials>WN</Initials><AffiliationInfo><Affiliation>Department of Neurology, Medical University Innsbruck, Innsbruck, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kohl</LastName><ForeName>Zacharias</ForeName><Initials>Z</Initials><AffiliationInfo><Affiliation>Department of Neurology, University of Regensburg, Regensburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hagenacker</LastName><ForeName>Tim</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Department of Neurology, University Medicine Essen, Essen, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruckes</LastName><ForeName>Christian</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>University Medical Center of the Johannes Gutenberg-University, Interdisciplinary Center for Clinical Trials (IZKS), Mainz, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Koch</LastName><ForeName>Birgit</ForeName><Initials>B</Initials><AffiliationInfo><Affiliation>Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Centre for ALS and other Motor Neuron Diseases, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spittel</LastName><ForeName>Susanne</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>G&#xfc;nther</LastName><ForeName>Kornelia</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michels</LastName><ForeName>Sebastian</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dorst</LastName><ForeName>Johannes</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Meyer</LastName><ForeName>Thomas</ForeName><Initials>T</Initials><AffiliationInfo><Affiliation>Charit&#xe9;-Universit&#xe4;tsmedizin Berlin, Corporate Member of Freie Universit&#xe4;t Berlin, Humboldt-Universit&#xe4;t zu Berlin, and Berlin Institute of Health, Centre for ALS and other Motor Neuron Diseases, Berlin, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Ambulanzpartner Soziotechnologie APST GmbH, Berlin, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ludolph</LastName><ForeName>Albert C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Neurology, Ulm University, Ulm, Germany.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>German Center for Neurodegenerative Diseases (DZNE), Site Ulm, Ulm, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>German Motor Neuron Disease Network (MND-NET)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D016449">Randomized Controlled Trial</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>JAMA Neurol</MedlineTA><NlmUniqueID>101589536</NlmUniqueID><ISSNLinking>2168-6149</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>S798V6YJRP</RegistryNumber><NameOfSubstance UI="D000077553">Edaravone</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>JAMA Neurol. 2022 Feb 1;79(2):117-118</RefSource><PMID Version="1">35006259</PMID></CommentsCorrections><CommentsCorrections RefType="ErratumIn"><RefSource>JAMA Neurol. 2022 Jun 13;:null</RefSource><PMID Version="1">35696158</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D061605" MajorTopicYN="N">Administration, Intravenous</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004311" MajorTopicYN="N">Double-Blind Method</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000077553" MajorTopicYN="N">Edaravone</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="Y">adverse effects</QualifierName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D010349" MajorTopicYN="N">Patient Compliance</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D017060" MajorTopicYN="N">Patient Satisfaction</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057216" MajorTopicYN="N">Propensity Score</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><CoiStatement><b>Conflict of Interest Disclosures:</b> Dr Witzel reported grants from the Charcot Foundation for ALS Research and the Medical Faculty of Ulm University outside the submitted work. Dr Maier reported personal fees from Merz Pharma GmbH outside the submitted work. Dr Grosskreutz reported grants from Deutsche Gesellschaft f&#xfc;r Muskelkranke eV, the Federal Ministry of Education and Research, and the Motor Neurone Disease Association, UK; and personal fees from Alexion, Biogen, and UCB outside the submitted work. Dr Petri reported grants from Deutsche Gesellschaft f&#xfc;r Muskelkranke, the EU Joint Programme&#x2013;Neurodegenerative Disease Research, and the German-Israeli Foundation; and personal fees from Biogen, ITF Pharma, and Roche outside the submitted work. Dr R. G&#xfc;nther reported personal fees from Biogen and Roche outside the submitted work. Dr Hermann reported grants from the Federal Ministry of Education and Research, Deutsche Gesellschaft f&#xfc;r Muskelkranke, the Helmholtz Foundation, Hermann und Lilly-Schilling-Stiftung f&#xfc;r medizinische Foschung im Stifterverband, and Innovationsausschuss des G-BA; and personal fees from Biogen and Desitin outside the submitted work. Dr Lingor reported personal fees from Desitin outside the submitted work; and holding a patent for EP 2825175 B1, US 9.980,972 B2 issued to University Medicine G&#xf6;ttingen. Dr L&#xf6;scher reported personal fees from Alexion, Alnylam, Akcea, Biogen, CSL Behring, Janssen, Kedrion, Sanofi, Pfizer, and Roche outside the submitted work. Dr Hagenacker reported grants from Biogen, Novartis Gene Therapies, Roche, and Sanofi-Genzyme; and personal fees from Alexion, Biogen, Novartis Gene Therapies, Roche, and Sanofi-Genzyme outside the submitted work. Dr Meyer reported grants from Apellis, Cytokinetics, and Orphazyme; personal fees from Biogen and Mitsubishi Tanabe Pharma; and cofounding Ambulanzpartner Soziotechnologie GmbH outside the submitted work. Dr Ludolph reported grants from Deutsche Forschungsgemeinschaft; and personal fees from Boehringer Ingelheim, Biogen, Desitin Pharma, Hoffmann-La Roche, Deutsche Gesellschaft f&#xfc;r Neurologie, Mitsubishi Tanabe Pharma, Novartis, Syneos Health, and Teva Pharmaceutical Industries outside the submitted work. No other disclosures were reported.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>1</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>3</Month><Day>9</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>1</Month><Day>10</Day><Hour>12</Hour><Minute>26</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35006266</ArticleId><ArticleId IdType="pmc">PMC8749709</ArticleId><ArticleId IdType="doi">10.1001/jamaneurol.2021.4893</ArticleId><ArticleId IdType="pii">2787473</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Brown RH, Al-Chalabi A. Amyotrophic lateral sclerosis. N Engl J Med. 2017;377(2):162-172. doi:10.1056/NEJMra1603471</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMra1603471</ArticleId><ArticleId IdType="pubmed">28700839</ArticleId></ArticleIdList></Reference><Reference><Citation>Spittel S, Maier A, Kettemann D, et al. . Non-invasive and tracheostomy invasive ventilation in amyotrophic lateral sclerosis: utilization and survival rates in a cohort study over 12 years in Germany. Eur J Neurol. 2021;28(4):1160-1171. doi:10.1111/ene.14647</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ene.14647</ArticleId><ArticleId IdType="pubmed">33210770</ArticleId></ArticleIdList></Reference><Reference><Citation>Bensimon G, Lacomblez L, Meininger V; ALS/Riluzole Study Group . A controlled trial of riluzole in amyotrophic lateral sclerosis. N Engl J Med. 1994;330(9):585-591. doi:10.1056/NEJM199403033300901</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJM199403033300901</ArticleId><ArticleId IdType="pubmed">8302340</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H, Kimura A. Investigation of the therapeutic effects of edaravone, a free radical scavenger, on amyotrophic lateral sclerosis (phase II study). Amyotroph Lateral Scler. 2006;7(4):241-245. doi:10.1080/17482960600881870</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/17482960600881870</ArticleId><ArticleId IdType="pubmed">17127563</ArticleId></ArticleIdList></Reference><Reference><Citation>Ito H, Wate R, Zhang J, et al. . Treatment with edaravone, initiated at symptom onset, slows motor decline and decreases SOD1 deposition in ALS mice. Exp Neurol. 2008;213(2):448-455. doi:10.1016/j.expneurol.2008.07.017</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.expneurol.2008.07.017</ArticleId><ArticleId IdType="pubmed">18718468</ArticleId></ArticleIdList></Reference><Reference><Citation>Aoki M, Warita H, Mizuno H, Suzuki N, Yuki S, Itoyama Y. Feasibility study for functional test battery of SOD transgenic rat (H46R) and evaluation of edaravone, a free radical scavenger. Brain Res. 2011;1382:321-325. doi:10.1016/j.brainres.2011.01.058</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.brainres.2011.01.058</ArticleId><ArticleId IdType="pubmed">21276427</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohta Y, Yamashita T, Nomura E, et al. . Improvement of a decreased anti-oxidative activity by edaravone in amyotrophic lateral sclerosis patients. J Neurol Sci. 2020;415:116906. doi:10.1016/j.jns.2020.116906</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2020.116906</ArticleId><ArticleId IdType="pubmed">32446009</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren Y, Wei B, Song X, et al. . Edaravone&#x2019;s free radical scavenging mechanisms of neuroprotection against cerebral ischemia: review of the literature. Int J Neurosci. 2015;125(8):555-565. doi:10.3109/00207454.2014.959121</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/00207454.2014.959121</ArticleId><ArticleId IdType="pubmed">25171224</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Itoyama Y, Sobue G, et al. ; Edaravone ALS Study Group . Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotroph Lateral Scler Frontotemporal Degener. 2014;15(7-8):610-617. doi:10.3109/21678421.2014.959024</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/21678421.2014.959024</ArticleId><ArticleId IdType="pmc">PMC4266079</ArticleId><ArticleId IdType="pubmed">25286015</ArticleId></ArticleIdList></Reference><Reference><Citation>Abe K, Aoki M, Tsuji S, et al. ; Writing Group; Edaravone (MCI-186) ALS 19 Study Group . Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2017;16(7):505-512. doi:10.1016/S1474-4422(17)30115-1</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(17)30115-1</ArticleId><ArticleId IdType="pubmed">28522181</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi F, Takei K, Tsuda K, Palumbo J. Post-hoc analysis of MCI186-17, the extension study to MCI186-16, the confirmatory double-blind, parallel-group, placebo-controlled study of edaravone in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):32-39. doi:10.1080/21678421.2017.1361442</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1361442</ArticleId><ArticleId IdType="pubmed">28872914</ArticleId></ArticleIdList></Reference><Reference><Citation>Takei K, Tsuda K, Takahashi F, Palumbo J. Post-hoc analysis of open-label extension period of study MCI186-19 in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):64-70. doi:10.1080/21678421.2017.1365372</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1365372</ArticleId><ArticleId IdType="pubmed">28872916</ArticleId></ArticleIdList></Reference><Reference><Citation>Shefner J, Heiman-Patterson T, Pioro EP, et al. . Long-term edaravone efficacy in amyotrophic lateral sclerosis: post-hoc analyses of Study 19 (MCI186-19). Muscle Nerve. 2020;61(2):218-221. doi:10.1002/mus.26740</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/mus.26740</ArticleId><ArticleId IdType="pmc">PMC7004197</ArticleId><ArticleId IdType="pubmed">31621933</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka M, Akimoto M, Palumbo J, Sakata T. A double-blind, parallel-group, placebo-controlled, 24-week, exploratory study of edaravone (MCI-186) for the treatment of advanced amyotrophic lateral sclerosis (ALS) (P3.191). Neurology. 2016;86(16 suppl):P3.191.</Citation></Reference><Reference><Citation>The Edaravone (MCI-186) ALS 16 Study Group. A post-hoc subgroup analysis of outcomes in the first phase III clinical study of edaravone (MCI-186) in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(sup1):11-19. doi:10.1080/21678421.2017.1363780</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1363780</ArticleId><ArticleId IdType="pubmed">28872917</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Chalabi A, Andersen PM, Chandran S, et al. . July 2017 ENCALS statement on edaravone. Amyotroph Lateral Scler Frontotemporal Degener. 2017;18(7-8):471-474. doi:10.1080/21678421.2017.1369125</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2017.1369125</ArticleId><ArticleId IdType="pubmed">28975816</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshino H. Edaravone for the treatment of amyotrophic lateral sclerosis. Expert Rev Neurother. 2019;19(3):185-193. doi:10.1080/14737175.2019.1581610</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/14737175.2019.1581610</ArticleId><ArticleId IdType="pubmed">30810406</ArticleId></ArticleIdList></Reference><Reference><Citation>European Medicine Agencies. Withdrawal assessment report: Radicava. May 24, 2019. Accessed May 26, 2021. https://www.ema.europa.eu/en/documents/withdrawal-report/withdrawal-assessment-report-radicava_en.pdf</Citation></Reference><Reference><Citation>Milne CP, Cohen JP, Felix A, Chakravarthy R. Impact of postapproval evidence generation on the biopharmaceutical industry. Clin Ther. 2015;37(8):1852-1858. doi:10.1016/j.clinthera.2015.05.514</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clinthera.2015.05.514</ArticleId><ArticleId IdType="pubmed">26143223</ArticleId></ArticleIdList></Reference><Reference><Citation>World Medical Association . World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013;310(20):2191-2194. doi:10.1001/jama.2013.281053</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2013.281053</ArticleId><ArticleId IdType="pubmed">24141714</ArticleId></ArticleIdList></Reference><Reference><Citation>Thoemmes F. Propensity score matching in SPSS. January 2012. Accessed May 26, 2021. https://ui.adsabs.harvard.edu/abs/2012arXiv1201.6385T</Citation></Reference><Reference><Citation>Brooks BR, Miller RG, Swash M, Munsat TL; World Federation of Neurology Research Group on Motor Neuron Diseases . El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1(5):293-299. doi:10.1080/146608200300079536</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/146608200300079536</ArticleId><ArticleId IdType="pubmed">11464847</ArticleId></ArticleIdList></Reference><Reference><Citation>Bharmal M, Payne K, Atkinson MJ, Desrosiers MP, Morisky DE, Gemmen E. Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications. Health Qual Life Outcomes. 2009;7(1):36. doi:10.1186/1477-7525-7-36</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1477-7525-7-36</ArticleId><ArticleId IdType="pmc">PMC2678998</ArticleId><ArticleId IdType="pubmed">19397800</ArticleId></ArticleIdList></Reference><Reference><Citation>F&#xfc;rstenau D, Klein S, Vogel A, Auschra C. Multi-sided platform and data-driven care research. Electron Markets. Published online March 23, 2021. doi:10.1007/s12525-021-00461-8</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12525-021-00461-8</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosenbaum PR, Rubin DB. Reducing bias in observational studies using subclassification on the propensity score. J Am Stat Assoc. 1984; 79(387):516-524. doi:10.1080/01621459.1984.10478078</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/01621459.1984.10478078</ArticleId></ArticleIdList></Reference><Reference><Citation>Lunetta C, Moglia C, Lizio A, et al. ; EDARAVALS Study Group . The Italian multicenter experience with edaravone in amyotrophic lateral sclerosis. J Neurol. 2020;267(11):3258-3267. doi:10.1007/s00415-020-09993-z</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00415-020-09993-z</ArticleId><ArticleId IdType="pubmed">32556567</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuss O, Blettner M, B&#xf6;rgermann J. Propensity score: an alternative method of analyzing treatment effects. Dtsch Arztebl Int. 2016;113:597-603. doi:10.3238/arztebl.2016.0597</Citation><ArticleIdList><ArticleId IdType="doi">10.3238/arztebl.2016.0597</ArticleId><ArticleId IdType="pmc">PMC5963493</ArticleId><ArticleId IdType="pubmed">27658473</ArticleId></ArticleIdList></Reference><Reference><Citation>Okada M, Yamashita S, Ueyama H, Ishizaki M, Maeda Y, Ando Y. Long-term effects of edaravone on survival of patients with amyotrophic lateral sclerosis. eNeurologicalSci. 2018;11:11-14. doi:10.1016/j.ensci.2018.05.001</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ensci.2018.05.001</ArticleId><ArticleId IdType="pmc">PMC6006910</ArticleId><ArticleId IdType="pubmed">29928711</ArticleId></ArticleIdList></Reference><Reference><Citation>Fortuna A, Gizzi M, Bello L, et al. ; Edaravone Study Group . Safety and efficacy of edaravone compared to historical controls in patients with amyotrophic lateral sclerosis from North-Eastern Italy. J Neurol Sci. 2019;404:47-51. doi:10.1016/j.jns.2019.06.006</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jns.2019.06.006</ArticleId><ArticleId IdType="pubmed">31325668</ArticleId></ArticleIdList></Reference><Reference><Citation>Abraham A, Nefussy B, Fainmesser Y, Ebrahimi Y, Karni A, Drory VE. Early post-marketing experience with edaravone in an unselected group of patients with ALS. Amyotroph Lateral Scler Frontotemporal Degener. 2019;20(3-4):260-263. doi:10.1080/21678421.2019.1572191</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2019.1572191</ArticleId><ArticleId IdType="pubmed">30784320</ArticleId></ArticleIdList></Reference><Reference><Citation>Vu M, Tortorice K, Zacher J, et al. . Assessment of use and safety of edaravone for amyotrophic lateral sclerosis in the Veterans Affairs health care system. JAMA Netw Open. 2020;3(10):e2014645. doi:10.1001/jamanetworkopen.2020.14645</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.14645</ArticleId><ArticleId IdType="pmc">PMC7536587</ArticleId><ArticleId IdType="pubmed">33017028</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull J. Is edaravone harmful? (a placebo is not a control). Amyotroph Lateral Scler Frontotemporal Degener. 2018;19(7-8):477-482. doi:10.1080/21678421.2018.1517179</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/21678421.2018.1517179</ArticleId><ArticleId IdType="pubmed">30373406</ArticleId></ArticleIdList></Reference><Reference><Citation>Turnbull J. Reappraisal of an ALS trial: unaccounted procedural risk. Lancet Neurol. 2020;19(9):717-718. doi:10.1016/S1474-4422(20)30265-9</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1474-4422(20)30265-9</ArticleId><ArticleId IdType="pubmed">32822626</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>